Volume 101, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

There is no abstract available for this article.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW, , 2010. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504512. [Google Scholar]
  2. Sundar S, Singh A, Agrawal N, Chakravarty J, , 2019. Effectiveness of single dose liposomal amphotericin B in visceral leishmaniasis in Bihar. Am J Trop Med Hyg 101: 795798. [Google Scholar]
  3. Singh OP, Hasker E, Boelaert M, Sundar S, , 2016. Elimination of visceral leishmaniasis on the Indian subcontinent. Lancet Infect Dis 16: e304e309. [Google Scholar]
  4. Khalil EA, 2014. Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial. PLoS Negl Trop Dis 8: e2613. [Google Scholar]
  5. Davidson RN, 1994. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 87: 7581. [Google Scholar]
  6. Fugisawa, 2000. Ambisome Label. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-740S001_AmBisome_prntlbl.pdf. Accessed July 21, 2019. [Google Scholar]
  7. Romero GAS, 2017. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: a multicenter, randomized, open label trial. PLoS Negl Trop Dis 11: e0005706. [Google Scholar]
  8. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD, , 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 76: 2532. [Google Scholar]
  9. Ben Salah A, 2013. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 368: 524532. [Google Scholar]
  10. Navin TR, Arana BA, Arana FE, Berman JD, Chajón JF, , 1992. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 165: 528534. [Google Scholar]
  11. Soto J, 2013. Intralesional antimony for single lesions of Bolivian cutaneous leishmaniasis. Clin Infect Dis 56: 12551260. [Google Scholar]
  12. Solomon M, Pavlotsky F, Leshem E, Ephros M, Trau H, Schwartz E, , 2011. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. J Eur Acad Dermatol Venereol 25: 973977. [Google Scholar]
  13. Solomon M, Pavlotzky F, Barzilai A, Schwartz E, , 2013. Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers. J Am Acad Dermatol 68: 284289. [Google Scholar]
  14. Marsden PD, Badaró R, Netto EM, Casler JD, , 1991. Spontaneous clinical resolution without specific treatment in mucosalleishmaniasis. Trans R Soc Trop Med Hyg 85: 221. [Google Scholar]
  15. Rocio C, Amato VS, Camargo RA, Tuon FF, Nicodemo AC, , 2014. Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients. Trans R Soc Trop Med Hyg 108: 176178. [Google Scholar]
  16. Guery R, 2017. Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: not a panacea. PLoS Negl Trop Dis 11: e0006094. [Google Scholar]
  17. Basher A, 2017. Case report: treatment of widespread nodular post kala-azar dermal leishmaniasis with extended-dose liposomal amphotericin B in Bangladesh: a series of four cases. Am J Trop Med Hyg 97: 11111115. [Google Scholar]
  18. den Boer M, Das AK, Akhter F, Burza S, Ramesh V, Ahmed BN, Zijlstra EE, Ritmeijer K, , 2018. Safety and effectiveness of short-course AmBisome in the treatment of post-kala-azar dermal leishmaniasis: a prospective cohort study in Bangladesh. Clin Infect Dis 67: 667675. [Google Scholar]
  19. Soto J, Rea J, Valderrama M, Toledo J, Valda L, Ardiles J, Berman J, , 2009. Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia. Am J Trop Med Hyg 81: 387389. [Google Scholar]
  20. Sundar S, Singh A, Chakravarty J, Rai M, , 2015. Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis. ScientificWorldJournal 2015: 414378. [Google Scholar]

Data & Media loading...

  • Received : 30 Jul 2019
  • Accepted : 02 Aug 2019
  • Published online : 03 Sep 2019

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error